Ascendis Pharma A/S vs Carvana Co — how do they compare? Ascendis Pharma A/S trades at $256.59 (market cap $16.67B), while Carvana Co trades at $71.09 (market cap $79.17B). The key difference: Carvana Co is far larger — about 4.7× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals.
| ASND | CVNA | |
|---|---|---|
Market Cap | $16.67B | $79.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $95.69 |
52-Week Low | $189.74 | $56.27 |
Enterprise Value | $17.04B | $81.65B |
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Carvana (CVNA) trades at $70.83, down 4.54% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported record Q2 2026 results with revenue up 52% year-over-year to $7.38 billion and net income of $513 million, though shares fell due to disappointing full-year EBITDA guidance. Strong cash flow generation continues with 2025 operating cash flow of $1.04 billion.
Outlook remains positive with analyst consensus price target of $87.18 implying 23% upside, but execution risks and premium valuation (P/E 38.1) temper enthusiasm. Key risks include profit margin compression and high debt levels despite improving leverage ratios. The stock faces near-term pressure from guidance concerns but maintains long-term growth potential.
Trailing returns across standard periods
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →